The Beta Agonist Lung Injury TrIal (BALTI) - prevention trial protocol
Open Access
- 15 March 2011
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 12 (1) , 1-6
Abstract
Acute lung injury complicates approximately 25-30% of subjects undergoing oesophagectomy. Experimental studies suggest that treatment with beta agonists may prevent the development of acute lung injury by decreasing inflammatory cell infiltration, activation and inflammatory cytokine release, enhancing basal alveolar fluid clearance and improving alveolar capillary barrier function. The Beta Agonist Lung Injury TrIal (prevention) is a multi-centre, randomised, double blind, placebo-controlled trial. The aim of the trial is to determine in patients undergoing elective transthoracic oesphagectomy, if treatment with inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and continued for 72 hours thereafter compared to placebo affect the incidence of early acute lung injury and other clinical, resource and patient focused outcomes. The primary outcome will be the development of acute lung injury within 72 hours of oesophagectomy. The trial secondary outcomes are the development of acute lung injury during the first 28 days post operatively; PaO2: FiO2 ratio; the number of ventilator and organ failure free days, 28 and 90 day survival; health related quality of life and resource utilisation. The study aims to recruit 360 patients from 10 UK centres. Current Controlled Trials ISRCTN47481946Keywords
This publication has 27 references indexed in Scilit:
- Outcomes following oesophagectomy in patients with oesophageal cancer: a secondary analysis of the ICNARC Case Mix Programme DatabaseCritical Care, 2009
- In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injuryThorax, 2008
- Alveolar edema fluid clearance and acute lung injuryRespiratory Physiology & Neurobiology, 2007
- In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injuryThorax, 2007
- Salmeterol enhances pulmonary fibrinolysis in healthy volunteersCritical Care Medicine, 2007
- Clinically relevant concentrations of β2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury*Critical Care Medicine, 2004
- Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort studyBMJ, 2003
- Salmeterol for the Prevention of High-Altitude Pulmonary EdemaNew England Journal of Medicine, 2002
- The Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000
- Report of the American-European Consensus Conference on acute respiratory distress syndrome: Definitions, mechanisms, relevant outcomes, and clinical trial coordinationJournal of Critical Care, 1994